Celldex Therapeutics, Inc. (CLDX) Competitors & Peers
The 5 largest companies in the same industry as Celldex Therapeutics, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $547.09 | P/E 35.2RSI 58Cap 138.9 B |
| REGN | Peer | $904.35 | P/E 20.0RSI 63Cap 93.6 B |
| ARGX | Peer | $927.21 | P/E 32.1RSI 56Cap 58.3 B |
| RVMD | Peer | $192.28 | RSI 50Cap 40.9 B |
| CSLLY | Peer | $34.65 | P/E 18.2RSI 71Cap 66.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- PFESupplier
Own 10-K customer-concentration disclosure: PfizerInc = 85% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - GSKNSupplier
Own 10-K customer-concentration disclosure: GlaxoSmithKlinePlc = 0% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BMYSupplier
Own 10-K customer-concentration disclosure: BristolMeyersSquibbCompany = 31% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- SNYCompetitor
Celldex's barzolvolimab targets similar severe inflammatory skin diseases served by Sanofi's Dupixent.
Model-inferred, unverified — treat as a lead, not evidence